Venrock Healthcare Capital Partners EG, L.P.
CIK 1808512 · last filed 2026-03-27
Venrock Healthcare Capital Partners EG, L.P. is a corporate insider who has filed 8 SEC Form 4 insider transactions across 2 companies since 2022. The most recent filing shows the insider sold $25.8M of KALV on Mar 27, 2026. Across all open-market trades the lifetime net is +$149.6M, making them a net buyer over the disclosed history. The firm reports its address in Palo Alto, CA. 42 SEC filings were submitted jointly with Bong Y Koh.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KALV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | 10%+ Owner | 5,089,354 | $27.00 | $137.41M | $49.93M | 6 | 2026-03-27 |
| Tricida, Inc. (TCDA) Delisted | 10%+ Owner | 9,851,080 | $0.11 | $1.06M | $99.62M | 2 | 2022-10-17 |
Recent Filings
8 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-27 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Sell (S) | −1,502,417 | -$25.84M | EDGAR |
| 2025-02-03 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +490,161 | $4.35M | EDGAR |
| 2024-01-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +642,628 | $9.03M | EDGAR |
| 2024-01-10 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +963,900 | $12.09M | EDGAR |
| 2024-01-05 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +415,583 | $5.04M | EDGAR |
| 2023-12-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +3,633,119 | $45.26M | EDGAR |
| 2022-10-17 | Tricida, Inc. (TCDA) Delisted | Buy (P) | +1,749,660 | $20.43M | EDGAR |
| 2022-09-07 | Tricida, Inc. (TCDA) Delisted | Buy (P) | +6,867,120 | $79.19M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.